Cargando…

Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience

OBJECTIVES: The treatments of limbic and other autoimmune encephalitis include immunosuppression, symptomatic treatment, and in the case of paraneoplastic syndromes, appropriate therapy for underlying neoplasms. When immunotherapy is considered, intravenous immunoglobulin is one option for treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinsella, JA, Irani, SR, Hollingsworth, R, O’Shaughnessy, D, Kane, P, Foster, M, Schott, JM, Lunn, MP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122256/
https://www.ncbi.nlm.nih.gov/pubmed/30202534
http://dx.doi.org/10.1177/2054270418793021
_version_ 1783352617290694656
author Kinsella, JA
Irani, SR
Hollingsworth, R
O’Shaughnessy, D
Kane, P
Foster, M
Schott, JM
Lunn, MP
author_facet Kinsella, JA
Irani, SR
Hollingsworth, R
O’Shaughnessy, D
Kane, P
Foster, M
Schott, JM
Lunn, MP
author_sort Kinsella, JA
collection PubMed
description OBJECTIVES: The treatments of limbic and other autoimmune encephalitis include immunosuppression, symptomatic treatment, and in the case of paraneoplastic syndromes, appropriate therapy for underlying neoplasms. When immunotherapy is considered, intravenous immunoglobulin is one option for treatment, either alone or in combination with corticosteroids. To date, however, evidence for the use of intravenous immunoglobulin in this context comes from case series/expert reviews as no controlled trials have been performed. We aimed to analyse the NHS England Database of intravenous immunoglobulin usage, which was designed to log use and guide procurement, to explore usage and therapeutic effect of intravenous immunoglobulin in autoimmune encephalitis in England. DESIGN: We conducted a retrospective audit and review of the NHS England Database on intravenous immunoglobulin use. SETTING: NHS England Database of intravenous immunoglobulin use which covers secondary and tertiary care prescribing and use of intravenous immunoglobulin for all patients in hospitals in England. PARTICIPANTS: Hospital in-patients with confirmed or suspected autoimmune/limbic encephalitis between September 2010 and January 2017. RESULTS: A total of 625 patients who were 18 years of age or older were treated with intravenous immunoglobulin for autoimmune encephalitis, of whom 398 were determined as having 'highly likely' or 'definite' autoimmune/limbic encephalitis. Ninety-six percent were treated with a single course of intravenous immunoglobulin. The availability and accuracy of reporting of outcomes was very poor, with complete data only available in 27% of all cases. CONCLUSIONS: This is the first review of data from this unique national database. Whilst there was evidence for clinical improvement in many cases of patients treated with intravenous immunoglobulin, the quality of outcome data was generally inadequate. Methods to improve quality, accuracy and completeness of reporting are crucial to maximise the potential value of this resource as an auditing tool.
format Online
Article
Text
id pubmed-6122256
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61222562018-09-10 Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience Kinsella, JA Irani, SR Hollingsworth, R O’Shaughnessy, D Kane, P Foster, M Schott, JM Lunn, MP JRSM Open Research OBJECTIVES: The treatments of limbic and other autoimmune encephalitis include immunosuppression, symptomatic treatment, and in the case of paraneoplastic syndromes, appropriate therapy for underlying neoplasms. When immunotherapy is considered, intravenous immunoglobulin is one option for treatment, either alone or in combination with corticosteroids. To date, however, evidence for the use of intravenous immunoglobulin in this context comes from case series/expert reviews as no controlled trials have been performed. We aimed to analyse the NHS England Database of intravenous immunoglobulin usage, which was designed to log use and guide procurement, to explore usage and therapeutic effect of intravenous immunoglobulin in autoimmune encephalitis in England. DESIGN: We conducted a retrospective audit and review of the NHS England Database on intravenous immunoglobulin use. SETTING: NHS England Database of intravenous immunoglobulin use which covers secondary and tertiary care prescribing and use of intravenous immunoglobulin for all patients in hospitals in England. PARTICIPANTS: Hospital in-patients with confirmed or suspected autoimmune/limbic encephalitis between September 2010 and January 2017. RESULTS: A total of 625 patients who were 18 years of age or older were treated with intravenous immunoglobulin for autoimmune encephalitis, of whom 398 were determined as having 'highly likely' or 'definite' autoimmune/limbic encephalitis. Ninety-six percent were treated with a single course of intravenous immunoglobulin. The availability and accuracy of reporting of outcomes was very poor, with complete data only available in 27% of all cases. CONCLUSIONS: This is the first review of data from this unique national database. Whilst there was evidence for clinical improvement in many cases of patients treated with intravenous immunoglobulin, the quality of outcome data was generally inadequate. Methods to improve quality, accuracy and completeness of reporting are crucial to maximise the potential value of this resource as an auditing tool. SAGE Publications 2018-09-03 /pmc/articles/PMC6122256/ /pubmed/30202534 http://dx.doi.org/10.1177/2054270418793021 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research
Kinsella, JA
Irani, SR
Hollingsworth, R
O’Shaughnessy, D
Kane, P
Foster, M
Schott, JM
Lunn, MP
Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
title Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
title_full Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
title_fullStr Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
title_full_unstemmed Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
title_short Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
title_sort use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the nhs experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122256/
https://www.ncbi.nlm.nih.gov/pubmed/30202534
http://dx.doi.org/10.1177/2054270418793021
work_keys_str_mv AT kinsellaja useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience
AT iranisr useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience
AT hollingsworthr useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience
AT oshaughnessyd useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience
AT kanep useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience
AT fosterm useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience
AT schottjm useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience
AT lunnmp useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience